Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Life Sciences Tools & Services · CIK 0000105770
$394.03
+0.14% · live
Updated
$28.37B market value
From WEST PHARMACEUTICAL SERVICES INC's FY2025 10-K, filed Feb 17, 2026 · read the filing
WEST PHARMACEUTICAL SERVICES makes medical devices and equipment. It took in $3.07B last year, which makes it a mid-sized company. Of every dollar it sells, about 16 cents is left as profit.
The financial picture is led by profitability, debt and accounting, with growth worth watching.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Recent open-market selling by Favorite Annette F, not under a pre-arranged plan.
$2.8M sold in the last 120 days · Read the filing
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
Strong finances across the board.
From WEST PHARMACEUTICAL SERVICES INC's FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Free cash flow
$276.4M → $468.9M
Cash
$484.6M → $791.3M
Capital spending
$377.0M → $285.9M
Revenue
$2.89B → $3.07B
Measured against FY2024, from the 10-K filed Feb 17, 2026
Improved: +69.6%
$276.4M to $468.9MCritical
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
How the latest move compares (quote live), and what was published around it
WST rose 0.14% on the latest quote. The average Health Care company tracked here moved +1.62%, and the S&P 500 −1.04%. That is 1.5 points below its sector and 1.2 points above the market.
No filing from WST and no news item about it appeared in the last 3 days.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 20% a year for the next 10 years. Over the last 10 years it grew by about 19% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 16 cents of every dollar of sales as profit, earning $493.7M last year.
Slowly. Sales grew 6.3% last year.
No — it holds more cash than debt, with $588.5M left over after paying off every borrowing. For every $1 it owes, it owns $3.90 in assets.
Core operating and valuation reference metrics
Whether the dividend is covered by what the business actually earns
It pays out 12 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 8% of the cash its operations generated. It has paid in each of the last 12 years.
GoodFigures from the FY2025 annual filing
Last year it earned $493.7M and generated $754.8M of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 17, 2026Filing for FY2025 | FY202410-K · Feb 18, 2025Filing for FY2024 | FY202310-K · Feb 18, 2025Filing for FY2023 | FY202210-K · Feb 18, 2025Filing for FY2022 | FY202110-K · Feb 22, 2022Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $3.07B | $2.89B | $2.95B | $2.89B | $2.83B | +6.3% |
| Cost of revenue | $1.97B | $1.89B | $1.82B | $1.75B | $1.66B | +4.0% |
| Gross profit | $1.10B | $998.5M | $1.13B | $1.14B | $1.18B | +10.6% |
| Gross marginGross profit ÷ revenueWhat is this? | 35.9% | 34.5% | 38.3% | 39.4% | 41.5% | +1.4 pts |
| Selling, general and administrative | $393.6M | $338.5M | $353.4M | $316.9M | $362.8M | +16.3% |
| Operating income | $584.9M | $569.9M | $676.0M | $734.0M | $752.3M | +2.6% |
| Operating marginOperating income ÷ revenueWhat is this? | 19.0% | 19.7% | 22.9% | 25.4% | 26.6% | −0.7 pts |
| Interest expense | $15.1M | $16.2M | $9.0M | $7.9M | $8.2M | −6.8% |
| Income before tax | $600.9M | $585.5M | $698.0M | $679.9M | $748.9M | +2.6% |
| Net income | $493.7M | $492.7M | $593.4M | $585.9M | $661.8M | +0.2% |
| Net marginNet income ÷ revenueWhat is this? | 16.1% | 17.0% | 20.1% | 20.3% | 23.4% | −1.0 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $6.86 | $6.81 | $8.07 | $7.91 | $8.92 | +0.6% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| WSTWEST PHARMACEUTICAL SERVICES INC · this page | 9.0/10 | 8/9 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Exercised stock options — 2,500 shares at $89.64 ($224.1K)
Holds 24,318 shares after this filing.
Sold on the open market — 2,500 shares at $345.00 ($862.5K)
Holds 21,818 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Quarterly report for Q2 FY2026
Revenue +13.8% · Gross profit +20.2% · Operating income +16.5% — against Q2 FY2025
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingWrite down why you are following WEST PHARMACEUTICAL SERVICES INC, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 40 subsidiaries named in its 10-K, incorporated across 23 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from WST's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 17, 2026), reported under the US GAAP taxonomy. View the source filing.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 9.0 | 8/9 | 10-K, filed Feb 17, 2026 |
| FY2024 | 8.0 | 5/9 | 10-K, filed Feb 18, 2025 |
| FY2023 | 9.0 | 6/9 | 10-K, filed Feb 20, 2024 |
| FY2022 | 9.0 | 6/9 | 10-K, filed Feb 21, 2023 |
| FY2021 | 9.0 | 8/9 | 10-K, filed Feb 22, 2022 |
| FY2020 | 10.0 | 7/9 | 10-K, filed Feb 23, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
8 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
18.54
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.79
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +63.3%
$484.6M to $791.3MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Changed: -24.2%
$377.0M to $285.9MSignificant
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Improved: +6.3%
$2.89B to $3.07BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +10.6%
$998.5M to $1.10BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +1.4 pts
34.5% to 35.9%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Jul 23, 2026 — read it.
Improved: +20.2%
$273.9M to $329.2MSignificant
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +16.5%
$153.7M to $179.1MSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +16.8%
$131.8M to $154.0MSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +19.3%
$1.83 to $2.19Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +13.8%
$766.5M to $872.3MNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +2.0 pts
35.7% to 37.7%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Deteriorated: -14.5%
$509.7M to $435.8MNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: -2.1%
71.9M to 70.4MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Jul 23, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Deteriorated: -16.4%
$521.4M to $435.8MSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +11.1%
$296.4M to $329.2MNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +11.0%
$138.8M to $154.0MNotable
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +2.7 pts
35.1% to 37.7%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: +1.2 pts
16.4% to 17.7%Notable
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +11.7%
$1.96 to $2.19Notable
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
8 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 17% and 23%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 22 analysts covering this company, as of . Their views, not this site's.
Of 22 analysts publishing on this company, 7 say strong buy, 14 say buy and 1 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 2.9% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 50.2x — a high multiple relative to the current trailing profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
| 6.3% |
| 16.1% |
| 57.46x |
| 0.34x |
| AAGILENT TECHNOLOGIES, INC. | 9.0/10 | 6/9 | 6.7% | 18.8% | 37.77x | 0.89x |
|---|
| IQVIQVIA HOLDINGS INC. | 6.0/10 | 5/9 | 5.9% | 8.3% | 34.71x | 3.59x |
|---|
| WATWATERS CORP /DE/ | 9.0/10 | 6/9 | 7.0% | 20.3% | 42.22x | 0.98x |
|---|
| MTDMETTLER TOLEDO INTERNATIONAL INC/ | 8.7/10 | 7/9 | 4.0% | 21.6% | 39.46x | -158.08x |
|---|
| RVTYREVVITY, INC. | 6.0/10 | 6/8 | 3.7% | 8.4% | 73.25x | 0.68x |
|---|
| CRLCHARLES RIVER LABORATORIES INTERNATIONAL, INC. | 2.0/10 | 4/8 | -0.9% | -3.6% | — | 1.24x |
|---|
| Median of peers | 7.3/10 | — | 4.9% | 13.6% | 39.46x | 0.94x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Exercised stock options — 2,500 shares at $89.64 ($224.1K)
Holds 24,318 shares after this filing.
Sold on the open market — 2,500 shares at $355.00 ($887.5K)
Holds 21,818 shares after this filing.
Exercised stock options — 2,524 shares at $89.64 ($226.3K)
Holds 24,342 shares after this filing.
Sold on the open market — 2,524 shares at $365.00 ($921.3K)
Holds 21,818 shares after this filing.
Exercised stock options — 2,817 shares at $83.47 ($235.1K)
Holds 19,662 shares after this filing.
Sold on the open market — 2,817 shares at $340.81 ($960.1K)
Holds 16,845 shares after this filing.
Exercised stock options — 2,818 shares at $83.47 ($235.2K)
Holds 19,663 shares after this filing.
Sold on the open market — 2,818 shares at $340.81 ($960.4K)
Holds 16,845 shares after this filing.
Exercised stock options — 2,500 shares at $89.64 ($224.1K)
Holds 19,345 shares after this filing.
Sold on the open market — 2,500 shares at $340.81 ($852.0K)
Holds 16,845 shares after this filing.
Exercised stock options — 794 shares
Holds 3,775 shares after this filing.
Had shares withheld to cover taxes — 346 shares at $351.37 ($121.4K)
Holds 3,429 shares after this filing.
Exercised stock options — 6,355 shares
Holds 9,784 shares after this filing.
Had shares withheld to cover taxes — 2,764 shares at $351.37 ($971.1K)
Holds 7,021 shares after this filing.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Signed a material agreement
Had a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingDisclosed a material cybersecurity incident
Read the filingDisclosed a material cybersecurity incident · Made a Regulation FD disclosure
Read the filingHeld a shareholder vote
Read the filingQuarterly report for Q1 FY2026
Revenue +21.0% · Operating margin +5.6 pts · Operating income +65.5% — against Q1 FY2025
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingProxy statement for a shareholder meeting
Read the filingHad a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingAnnual report for FY2025
Revenue +6.3% · Free cash flow +69.6% · Cash +63.3% — against FY2024
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingQuarterly report for Q3 FY2025
Revenue +7.7% · Cash +28.0% · Gross profit +11.2% — against Q3 FY2024
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join
Read the filingQuarterly report for Q2 FY2025
Revenue +9.2% · Operating margin +2.1 pts · Long-term debt +177.9% — against Q2 FY2024
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join
Read the filingHad a director or senior officer leave or join
Read the filingSource: Exhibit 21 of the 10-K filed 2026-02-17. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
West Declares Quarterly Dividend
Yahoo ·
This 146-Old Can Maker Is On a Winning Streak Unseen In Its Half-Century Stock History
Benzinga ·
3 Low-Volatility Stocks We’re Skeptical Of
Yahoo ·
West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally?
Yahoo ·
Meta, JPMorgan, West Pharmaceutical And More: CNBC’s ‘Final Trades’
Benzinga ·
Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms
Yahoo ·
Final Trades: JP Morgan, Meta, West Pharmaceutical Services and the iShares U.S. Energy ETF
CNBC ·
Inexpensive Stocks Found In This Sector
Benzinga ·
TD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $420
Benzinga ·
Top 50 High-Quality Dividend Growth Stocks For October 2026
SeekingAlpha ·
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y
Yahoo ·
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
Yahoo ·
Primary sources and further research